Clinical trial
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
NCT00270452 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00270452 |
|---|---|
| Title | Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome |
| Official title | Safety of WT1 and PR1 Peptide Vaccination for Patients With Myeloid Malignancies |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome (MDS) |
| Intervention type | Drug |
| Interventions | WT1 and PR1 Peptide Vaccine |
| Enrollment | 9 |
| Start date | Dec 22, 2005 |
| Primary completion | Oct 26, 2007 |
| Completion | Oct 26, 2007 |
| First posted | Dec 26, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: